With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

The healthcare worker warns that most people will put two thirds of the weight back on within a year of coming off the ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...